Oxervate (Cenegermin-bkbj) is a prescription eye drop solution indicated for the treatment of neurotrophic keratitis (NK), a progressive eye condition characterized by a loss of corneal sensation. This rare condition may lead to persistent epithelial defects and corneal damage, which can potentially impair vision.

The medication is used to support the healing of the corneal surface in patients diagnosed with NK. This treatment may be associated with the resolution of persistent corneal defects, which in turn may help to alleviate associated symptoms, such as ocular discomfort and irritation. Clinical use involves patients across all stages of the condition. The overall goal is to support the restoration of the cornea's structural integrity.

Quick Fact: Treatment for Corneal Damage

Oxervate is designed to address the damage caused by NK, aiding the natural process of healing the outer layer of the cornea. This action supports the resolution of persistent defects that are often resistant to conservative management.

Who Can and Cannot Use Oxervate?

This section explains the population-eligibility rules for Oxervate (Cenegermin-bkbj), based strictly on official regulatory labeling.

Eligibility Scope

Classification	Status According to Regulatory Documents
Absolute Contraindications	None are listed in the official prescribing information.
Established Age Range	Patients 2 years of age and older. Safety and effectiveness have not been established in patients less than two years old.
Geriatric Use	Established, with no dose adjustment required for patients 65 years and older.

Conditional Restrictions on Use

Oxervate use is subject to specific limitations documented in the labeling:

• Active Eye Infection: Treatment should not be initiated until any active eye infection has been fully treated and resolved.
• Contact Lens Use: Patients must remove contact lenses before applying the eye drops. Lenses may be reinserted 15 minutes after administration.

Organ Function and Pregnancy Status

• Renal/Hepatic Impairment: No dose adjustment is considered necessary for patients with renal or hepatic impairment.
• Pregnancy/Lactation: No human data are available to inform risks during pregnancy. It is unknown if the medicine is excreted in human milk during lactation.

Interactions with other medicines and products

Oxervate (cenegermin-bkbj) has a specialized interaction profile defined by its limited exposure beyond the eye surface. Regulatory documents state that dedicated studies with systemic medicines have not been performed, and no drug-drug interactions are anticipated because systemic absorption of cenegermin is negligible or undetectable.

The official interaction concerns are limited to the local ocular environment and fall into two primary categories:

• Local Ocular Interference: Co-administration with topical ophthalmic agents known to inhibit epithelial healing should be avoided. These agents include ophthalmic corticosteroids and eye drops containing certain preservatives, such as benzalkonium chloride or cetrimide, due to the risk of diminishing the medicine's intended effect.

• Administration Timing Rules: To ensure proper distribution and prevent dilution, a mandatory 15-minute separation is required between Oxervate and any other topical ophthalmic product. Oxervate must be applied first before any viscous drops, gels, or eye ointments, with the same 15-minute waiting period observed. Contact lenses must also be removed prior to application and reinserted 15 minutes afterward.

How Oxervate Works: Mechanism of Action

---

Targeted Agonism of Nerve Growth Factor (NGF) Receptors

Cenegermin functions as a targeted agonist, a molecule that mimics the body's natural signaling substance by binding to and activating the high-affinity tropomyosin receptor kinase A ( TrkA) and low-affinity p75 neurotrophin receptor ( p75NTR) on corneal cells. This action delivers an exogenous Nerve Growth Factor (NGF) ligand, thereby modulating the signal transduction pathways at the site of action.

---

Cascade for Neuroprotection and Epithelial Regeneration

Receptor activation triggers crucial intracellular signaling cascades, notably the PI3K/Akt and MAPK/ERK pathways. The PI3K/Akt pathway supports neuronal survival, while the MAPK/ERK pathway stimulates corneal epithelial cell proliferation and migration. This dual effect promotes the regeneration of corneal nerve fibers and facilitates the maintenance of corneal epithelial integrity.

---

Modulation of Corneal Regenerative Pathways

The mechanism's primary physiological consequence involves the modulation of corneal regenerative pathways. By facilitating neurite outgrowth and epithelial cell turnover, the drug engages mechanisms responsible for tissue maintenance, influencing activity within the targeted pathways.

Official Administration Guide

Oxervate (cenegermin-bkbj) is an ophthalmic solution administered into the conjunctival sac of the affected eye(s). It is approved for use in adults and children aged 2 years and older.

Dosing Schedule

The recommended dose is one drop per affected eye, 6 times a day at approximately 2-hour intervals, starting in the morning. The full course of treatment is a fixed duration of eight weeks.

Administration Scope	Detail
Route of Administration	Topical Ophthalmic Instillation
Dosing	One drop
Frequency/Timing	6 times a day, 2 hours apart, for 8 weeks
Age Group	Adults and children ge 2 years
Missed Dose Rule	Continue treatment as normal at the next scheduled time; do not take an extra dose.

Procedural Requirements

The medicine is supplied frozen and must be thawed, not shaken, prior to use. Patients must use the provided Delivery System Kit components (vial adapters, pipettes, and sterile disinfectant wipes) for each administration. A new pipette and wipe must be used for every dose.

• The vial adapter must be connected to the vial and cleaned with a wipe before attaching the pipette for dose withdrawal.
• The opened vial, with the adapter connected, must be stored in the refrigerator or at room temperature (below 25°C) and discarded no later than 12 hours after the adapter was first connected.
• Contact lenses must be removed before applying the drop and may be reinserted 15 minutes after the administration is complete.
• If using other topical eye drops, administer them at least 15 minutes apart to prevent dilution. If using an eye ointment, gel, or viscous drop, administer Oxervate first and wait 15 minutes before applying the more viscous product.

I. Evidence for Use in Moderate to Severe Neurotrophic Keratitis (NK)

Cenegermin (the active component in Oxervate) was studied for its use in moderate to severe Neurotrophic Keratitis (NK), a condition marked by persistent epithelial defects. The primary evidence base consists of two short-term, randomized, controlled, double-masked studies that research examined against a vehicle (placebo) comparator group. These pivotal studies primarily observed responses over a defined 8-week treatment period.

---

II. Study Focus on Key Outcomes: Healing and Recurrence

These controlled trials research examined a primary outcome related to the proportion of participants who achieved Complete Corneal Healing, which reflects the resolution of the corneal defect. Findings describe patterns observed in the studies related to measurements of complete healing when comparing the Cenegermin group to the vehicle group. Follow-up research also explored the durability of healing by studying the recurrence rate of the defect.

---

III. Long-Term Studies and Durability of Effect

The two main controlled trials included follow-up phases that monitored patients for periods ranging up to approximately one year (48 to 56 weeks). Evidence derived from observational settings has also been utilized, with some data showing patterns related to outcomes up to three to four years post-treatment; however, these longer studies were not randomized or controlled. Data are still emerging regarding the sustained effect of Cenegermin, and long-term effects are not fully established by randomized evidence.

---

IV. Evidence in Special and Underserved Populations

The research was evaluated in adult patients (aged 18 years and older). Data for certain groups remain insufficient, including pediatric populations (children 2 to 17 years old) and patients with milder disease (Stage 1). For these groups, certainty remains low due to differences in study design and modest sample sizes. Consequently, the long-term patterns related to healing and recurrence data are still emerging and certainty remains low.

Common questions about Oxervate (FAQ)

---

Q: What is the difference between Oxervate and conventional dry eye treatments?

Oxervate is prescribed to treat neurotrophic keratitis, a specific and severe corneal condition. It belongs to a unique class of medicines called recombinant human nerve growth factors, as it is intended to address the underlying nerve damage. Conventional dry eye treatments are typically supportive, such as lubricants, and generally do not address the function of the corneal nerves.

---

Q: Can pregnant or breastfeeding individuals use Oxervate?

According to the official product information, there are no human data available to inform any drug-associated risks during pregnancy. Similarly, it is unknown if the active medicine is excreted into human milk during lactation. These are points of regulatory uncertainty.

---

Q: Is Oxervate the only treatment available for neurotrophic keratitis?

Official documentation describes Oxervate as the first pharmacologic treatment approved by the FDA that specifically addresses the underlying cause of neurotrophic keratitis. The product is characterized by its mechanism that involves addressing nerve function. Other supportive and surgical options may exist.

---

Q: Can Oxervate be used to treat other types of dry eye, besides neurotrophic keratitis?

The official regulatory label indicates that Oxervate (cenegermin-bkbj) is only indicated for the treatment of neurotrophic keratitis. Its use is limited to this specific, sight-threatening condition.

---

Q: How quickly do people typically start to notice anything after starting Oxervate?

Clinical studies were designed to evaluate the primary outcome of complete corneal healing at the end of the 8-week treatment period. However, research indicated that more than half of the patients who eventually achieved complete healing had done so by week 4 of the treatment course.

---

Q: What are the most commonly reported side effects that are NOT eye-related?

While most common side effects are related to the eye, the official list of Common side effects (occurring in at least 1 in 100 people) includes headache, which is a non-eye-related event.

---

Q: Are there any foods or drinks I should avoid while using Oxervate?

Official drug information and patient guidance do not list any specific foods or drinks that must be avoided while using Oxervate.

---

Q: Does Oxervate require a special type of prescription?

Oxervate is a highly specialized, prescription-only product. Due to its targeted use, authorization criteria often involve prescriptions being initiated by or in consultation with an ophthalmologist or corneal specialist.

---

Q: Does using Oxervate affect my ability to drive?

The regulatory side effect list includes potential adverse reactions like eye pain and photophobia (light sensitivity). These effects could potentially interfere with vision or driving ability immediately after the drops are applied.

---

Q: Can I use Oxervate if I have had previous eye surgery?

The regulatory label advises caution and monitoring for patients with a history of ocular cancer because the active substance is a growth factor that can stimulate cell growth. General eye surgery history is not specifically addressed as a contraindication.

---

Q: Is there a generic version of Oxervate available?

Oxervate (cenegermin-bkbj) is currently protected by regulatory exclusivity for its approved indication. According to official records, no generic version of Oxervate is currently approved or available.

---

Q: Can I travel with Oxervate, considering the temperature requirements?

The medicine requires strict temperature control. Unopened cartons must be stored refrigerated between 36 F to 46 F (2 C to 8 C). The product is often shipped with an insulated pack to help maintain this necessary temperature during travel and transport.

---

Q: What if I experience blurry vision after applying the drop?

While blurry vision is not explicitly listed as a common side effect in official documents, common side effects like eye pain or a foreign body sensation may be experienced immediately after application and could temporarily interfere with vision.

---

Q: Does the drug have any known interactions with alcohol consumption?

Regulatory documents state that systemic absorption of cenegermin is negligible or undetectable. For this reason, official information indicates no drug-drug interactions are anticipated, and there are no specific warnings or guidance regarding alcohol consumption.

---

Q: Is there a chance the neurotrophic keratitis will come back after using Oxervate?

Follow-up research examined the durability of healing achieved after the 8-week treatment course. Evidence from pivotal studies indicated that a recurrence of the corneal defect occurred in approximately 14% to 20% of patients who achieved complete corneal healing.

---

Q: Can I use Oxervate if I am taking blood thinners?

Regulatory documents state that no drug-drug interactions are anticipated with systemic medications like blood thinners. This is because systemic absorption of the active medicine, cenegermin, is described as negligible or undetectable.

How to Store and Dispose of Oxervate (cenegermin-bkbj)

Oxervate ophthalmic solution has strict storage and handling requirements to maintain the stability of the medicine.

Storage Conditions

Item	Requirement
Unopened Cartons	Store in a refrigerator between 36 F to 46 F (2 C to 8 C) in the original carton.
Opened Vials	Must be used within 12 hours of opening. Can be stored during this period at room temperature (up to 77 F) or refrigerated.
Handling Restrictions	The product must not be frozen after receipt and must not be shaken.
Child Safety	Keep strictly out of the sight and reach of children.

Disposal

The used vial and single-use pipette must be thrown away after the 12-hour use period. Any unused or expired medicine must be disposed of according to local pharmaceutical waste regulations.